Candel Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Candel Therapeutics (CADL)

Candel Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Candel Therapeutics (CADL)

PR Newswire

Candel raised $80 million from investors in part to prepare its aglatimagene BLA. On November 12, 2026, the submission slipped to mid-2027 and CADL fell over 26%, prompting an investigation into potential securities law violations tied to that BLA timeline.

NEW YORK, Nov. 16, 2026 /PRNewswire/ — More than 26% of the value of Candel Therapeutics (NASDAQ: CADL) shares was wiped out after the Company announced on November 12, 2026 that it now expects to submit its Biologics License Application (BLA) for aglatimagene in localized prostate cancer in mid-2027 instead of the fourth quarter of 2026. If you bought CADL and are now holding a loss, you are encouraged to submit your CADL loss details today or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Levi & Korsinsky, LLP

That BLA was a stated use of investor money. In December 2024, Candel announced an $80 million public offering. In a Form 8-K, it said it intended to use the net proceeds to continue development of its product candidates, “including preparing submission of a Biologics License Application for CAN-2409 in prostate cancer.” CAN-2409 is aglatimagene.

The same November 12 disclosure came with a new $50 million at-the-market equity program. Candel’s Form 10-Q, also dated November 12, stated: “We will require additional capital to commercialize aglatimagene in early localized prostate cancer.” The Company cited “timelines associated with certain assay refinement” and ongoing FDA dialogue for the delay. The investigation concerns whether Candel may not have adequately disclosed BLA timing risks before CADL shares fell.

Lost money on CADL? Start your free CADL loss review or call (212) 363-7500.

Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Billions recovered.

Frequently Asked Questions About the CADL Investigation

Q: How much did CADL stock drop?A: Shares fell approximately $2.19, or about 26% after the Company disclosed on November 12, 2026 that it now expects to submit its aglatimagene BLA in mid-2027 rather than the fourth quarter of 2026. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Candel Therapeutics made materially false or misleading statements regarding the anticipated fourth-quarter 2026 timing of its aglatimagene BLA submission. When the Company disclosed that the submission had moved to mid-2027, the stock price declined sharply.

Q: Who is eligible to participate in the CADL investigation?A: Investors who purchased CADL stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What do CADL investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my CADL shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CADL and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:

Levi & Korsinsky, LLP 

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/candel-therapeutics-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-candel-therapeutics-cadl-302940820.html

SOURCE Levi & Korsinsky, LLP